We are live on ! Find out more
GILD icon

Gilead Sciences

1,522 hedge funds and large institutions have $72.7B invested in Gilead Sciences in 2018 Q2 according to their latest regulatory filings, with 76 funds opening new positions, 544 increasing their positions, 725 reducing their positions, and 107 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 78.96%79% (+0.04%)

3% less funds holding

Funds holding: 1,5631,522 (-41)

6% less capital invested

Capital invested by funds: $77.5B → $72.7B (-$4.82B)

22% less funds holding in top 10

Funds holding in top 10: 6047 (-13)

25% less repeat investments, than reductions

Existing positions increased: 544 | Existing positions reduced: 725

29% less first-time investments, than exits

New positions opened: 76 | Existing positions closed: 107

31% less call options, than puts

Call options by funds: $1.25B | Put options by funds: $1.82B

Holders
1,522
Holders Change
-41
Holders Change %
-2.62%
% of All Funds
34.84%
Holding in Top 10
47
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-21.67%
% of All Funds
1.08%
New
76
Increased
544
Reduced
725
Closed
107
Calls
$1.25B
Puts
$1.82B
Net Calls
-$567M
Net Calls Change
-$452M
Name Holding Trade Value Shares
Change
Change in
Stake
GG
301
Gofen & Glossberg
Illinois
$14.9M -$275K -3,897 -2%
MSV
302
MN Services Vermogensbeheer
Netherlands
$14.8M +$261K +3,700 +2%
OA
303
Oak Associates
Ohio
$14.8M +$600K +8,491 +4%
SC
304
Scotia Capital
Ontario, Canada
$14.6M +$400K +5,660 +3%
UIM
305
Underhill Investment Management
California
$14.6M +$131K +1,850 +0.9%
CIBC Private Wealth Group
306
CIBC Private Wealth Group
Georgia
$14.5M +$1.33M +18,894 +10%
CGH
307
Crossmark Global Holdings
Texas
$14.4M -$38.8K -550 -0.3%
FWCM
308
Ferguson Wellman Capital Management
Oregon
$14.4M +$11.8M +167,280 +472%
MIM
309
Marco Investment Management
Georgia
$14.2M +$42.6K +603 +0.3%
TA
310
Tamarack Advisers
California
$14.2M +$2.47M +35,000 +21%
BFM
311
Boston Financial Management
Massachusetts
$14M -$338K -4,783 -2%
SCM
312
SKBA Capital Management
California
$14M -$113K -1,600 -0.8%
Edgewood Management
313
Edgewood Management
Connecticut
$14M -$811K -11,487 -5%
ACM
314
Argent Capital Management
Missouri
$13.9M +$345K +4,885 +3%
MA
315
MUFG Americas
New York
$13.8M -$348K -4,922 -2%
TAF
316
Tredje AP-fonden
Sweden
$13.8M +$264K +3,737 +2%
AB
317
Amalgamated Bank
New York
$13.7M +$754K +10,671 +6%
SH
318
SeaTown Holdings
Singapore
$13.6M +$8.99M +127,286 +196%
SOADOR
319
State of Alaska Department of Revenue
Alaska
$13.4M +$2.64M +37,380 +25%
DP
320
Dearborn Partners
Illinois
$13.3M -$357K -5,052 -3%
Creative Planning
321
Creative Planning
Kansas
$13.2M +$966K +13,676 +8%
SCM
322
Shelton Capital Management
Colorado
$13.1M +$304K +4,309 +2%
LWCFA
323
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$13M -$13.5M -191,193 -51%
MSA
324
Mason Street Advisors
Wisconsin
$12.9M -$3.18K -45 -0%
AAF
325
Andra AP-fonden
Sweden
$12.7M +$1.24M +17,600 +11%

GILD Hedge Fund Activity: Q2 2018 in Review

1,522 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2018, worth a combined $72.7B — down 6.2% from $77.5B a quarter earlier.

Sellers outnumbered buyers: 107 funds closed out of GILD and 76 opened new positions — a net loss of 31 holders — while 725 trimmed existing stakes and 544 added.

The largest buyer was Capital Research Global Investors, adding an estimated $995M. The largest seller was Fidelity Investments, cutting an estimated $361M.

  • 1,522 institutional investors held Gilead Sciences (GILD) as of Q2 2018, down from 1,563 in Q1 2018.
  • Funds reported $72.7B of Gilead Sciences stock for Q2 2018, down 6.2% quarter-over-quarter.
  • 76 funds opened new Gilead Sciences positions in Q2 2018 and 107 closed out, a net change of -31 holders.
  • The largest Gilead Sciences buyer in Q2 2018 was Capital Research Global Investors, an estimated $995M added.
  • The largest Gilead Sciences seller in Q2 2018 was Fidelity Investments, an estimated $361M sold.

Based on aggregated 13F filings for Q2 2018.